脑机接口技术加速从实验室走向临床，中国又有新突破

Core Viewpoint - The approval of the invasive brain-computer interface (BCI) product by Jingyu Medical Technology marks a significant milestone in the treatment of drug addiction, particularly for opioid dependence, showcasing the potential of BCI technology in serious medical applications [1][2][3]. Group 1: Product and Technology - Jingyu Medical's invasive brain deep stimulation system is the first globally approved BCI product for treating addiction-related mental disorders, specifically targeting difficult-to-treat moderate to severe opioid addiction [1][2]. - The system utilizes a dual-target technology to stimulate key brain areas, namely the nucleus accumbens and the anterior limb of the internal capsule, providing a new treatment option for patients [2][3]. - Clinical studies indicated that after implantation, patients showed improvements in negative emotions associated with addiction, with a 62.5% non-recurrence rate after 10 years of follow-up for the first batch of cases [2][3]. Group 2: Industry Landscape - The BCI industry is characterized by a diversified competitive landscape, with invasive and non-invasive technologies being developed for various applications, including medical and consumer sectors [4][6]. - Invasive BCIs are primarily focused on medical applications, while non-invasive BCIs are being utilized in consumer products and industrial applications [4][6]. - The global BCI market is projected to reach approximately $2.46 billion in 2024 and exceed $10.8 billion by 2033, with a compound annual growth rate (CAGR) of 16.5% [5]. Group 3: Future Trends and Challenges - The BCI industry is expected to experience rapid development, with trends including accelerated technology integration, expanded application scenarios, and improved industry chain collaboration [7]. - Despite the promising outlook, the industry faces challenges such as technical barriers, ethical considerations, and the need for regulatory compliance [8]. - Jingyu Medical plans to initiate international multi-center clinical trials to contribute to global addiction treatment solutions, aiming for BCI technology to become a standard treatment method for neurological disorders [9].